Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05950165
Title A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Cho Pharma Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Renovatio Clinical WITHDRAWN The Woodlands Texas 77389 United States Details
Taipei Medical University - Shuang Ho Hospital - Oncology RECRUITING New Taipei City Taipei Special Municipality 23561 Taiwan Details
Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital - Hemato-Oncology RECRUITING Kaohsiung 833 Taiwan Details
China Medical University Hospital - Hematology/Oncology - Taichung RECRUITING Taichung City 404 Taiwan Details
National Cheng Kung University Hospital - Internal Medicine RECRUITING Tainan 70403 Taiwan Details
National Taiwan University Hospital - Hematology And Oncology RECRUITING Taipei 100 Taiwan Details
Tri-Service General Hospital - Neihu Branch - Hematology RECRUITING Taipei 11490 Taiwan Details
Chang Gung Medical Foundation - LinKou Chang Gung Memorial Hospital - Hematology and Oncology - Hematology and Oncology TERMINATED Taoyuan 33305 Taiwan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field